A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, 'Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.'
Apr 10 2024Oncotarget A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin -resistance in acute myeloid leukemia ."
Acute myeloid leukemia is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. In this new study, researchers Simonetta I.
"Given the role of GHRH in multiple cancer types, it is possible that GHRH antagonists may offer an alternative treatment approach for AML as well as drug-resistant AML, which may circumvent the side effects associated with standard chemotherapy." The in vitro results revealed a significant reduction in cell viability for all treated wild-type cells. Doxorubicin-resistant clones were similarly susceptible to MIA-602 as the wild-type counterpart. Their in vivo experiment of xenografted nude mice with Doxorubicin-resistant K-562 revealed a reduction in tumor volume with MIA-602 treatment compared to control.
"Our study demonstrates that these three AML cell lines, and their Doxorubicin-resistant clones, are susceptible to GHRH antagonist MIA-602."Journal reference:Gaumond, S. I., et al. . Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia. Oncotarget. doi.org/10.18632/oncotarget.28579.
Doxorubicin Leukemia Myeloid Leukemia Bone Bone Marrow Cancer Cell Chemotherapy Growth Hormone Hormone Oncology Proliferation Research
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study finds outcomes after stem cell transplant in elderly patients with AML have improved since 2000According to a study published in Clinical Cancer Research, among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.
Read more »
ABT199/Venetoclax synergism with thiotepa in acute myeloid leukemia (AML) cellsA new research paper titled 'ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells' has been published in Oncotarget.
Read more »
Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplantAmong patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.
Read more »
A new antibody capture method reveals G-quadruplex landscape and its regulationA new research paper was published in Oncotarget entitled, 'G-quadruplex landscape and its regulation revealed by a new antibody capture method.'
Read more »
Vitamin D shows promise in targeting aging's biological mechanisms, study findsWhat is currently known about the potential effect of vitamin D (VitD) on modulating some hallmarks of aging.
Read more »
Study shows heat mitigation improves worker safety and the bottom lineClimate change is a major factor in laborer safety. A new study from UConn's Korey Stringer Institute shows how heat mitigation can help keep workers safe and productive.
Read more »